These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1088 related articles for article (PubMed ID: 29213270)

  • 21. Nanobodies: The "Magic Bullets" in therapeutics, drug delivery and diagnostics.
    Mir MA; Mehraj U; Sheikh BA; Hamdani SS
    Hum Antibodies; 2020; 28(1):29-51. PubMed ID: 31322555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies.
    Romao E; Morales-Yanez F; Hu Y; Crauwels M; De Pauw P; Hassanzadeh GG; Devoogdt N; Ackaert C; Vincke C; Muyldermans S
    Curr Pharm Des; 2016; 22(43):6500-6518. PubMed ID: 27669966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors.
    Hambach J; Mann AM; Bannas P; Koch-Nolte F
    Front Immunol; 2022; 13():1005800. PubMed ID: 36405759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generation and characterization of nanobodies targeting GPCR.
    Zhang S; Fan Z; Liu J
    Biophys Rep; 2024 Feb; 10(1):22-30. PubMed ID: 38737476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions.
    Bobkov V; Zarca AM; Van Hout A; Arimont M; Doijen J; Bialkowska M; Toffoli E; Klarenbeek A; van der Woning B; van der Vliet HJ; Van Loy T; de Haard H; Schols D; Heukers R; Smit MJ
    Biochem Pharmacol; 2018 Dec; 158():413-424. PubMed ID: 30342023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a Recombinant Monospecific Anti-PLGF Bivalent Nanobody and Evaluation of it in Angiogenesis Modulation.
    Nikooharf A; Arezumand R; Mansouri K; Khoshi AH; Namdar Ahmadabad H
    Mol Biotechnol; 2020 Dec; 62(11-12):580-588. PubMed ID: 32975735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanobodies: from structure to applications in non-injectable and bispecific biotherapeutic development.
    Li B; Qin X; Mi LZ
    Nanoscale; 2022 May; 14(19):7110-7122. PubMed ID: 35535618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NanoBERTa-ASP: predicting nanobody paratope based on a pretrained RoBERTa model.
    Li S; Meng X; Li R; Huang B; Wang X
    BMC Bioinformatics; 2024 Mar; 25(1):122. PubMed ID: 38515052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanobodies as versatile tools: A focus on targeted tumor therapy, tumor imaging and diagnostics.
    Al-Baradie RS
    Hum Antibodies; 2020; 28(4):259-272. PubMed ID: 32831197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors.
    Eichhoff AM; Börner K; Albrecht B; Schäfer W; Baum N; Haag F; Körbelin J; Trepel M; Braren I; Grimm D; Adriouch S; Koch-Nolte F
    Mol Ther Methods Clin Dev; 2019 Dec; 15():211-220. PubMed ID: 31687421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanobodies that Neutralize HIV.
    Weiss RA; Verrips CT
    Vaccines (Basel); 2019 Jul; 7(3):. PubMed ID: 31370301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanobody-based cancer therapy of solid tumors.
    Kijanka M; Dorresteijn B; Oliveira S; van Bergen en Henegouwen PM
    Nanomedicine (Lond); 2015 Jan; 10(1):161-74. PubMed ID: 25597775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation, expression and utilization of single-domain antibodies for in vivo protein localization and manipulation in sea urchin embryos.
    Schrankel CS; Gökirmak T; Lee CW; Chang G; Hamdoun A
    Methods Cell Biol; 2019; 151():353-376. PubMed ID: 30948018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Production and Characterization of Novel Camel Single Domain Antibody Targeting Mouse Vascular Endothelial Growth Factor.
    Kazemi-Lomedasht F; Behdani M; Habibi-Anbouhi M; Shahbazzadeh D
    Monoclon Antib Immunodiagn Immunother; 2016 Jun; 35(3):167-71. PubMed ID: 27167350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Application of nanobody in cancer treatment].
    Wu Y; Hao X; Li M
    Sheng Wu Gong Cheng Xue Bao; 2017 Jul; 33(7):1085-1090. PubMed ID: 28869728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural Basis of Epitope Recognition by Heavy-Chain Camelid Antibodies.
    Zavrtanik U; Lukan J; Loris R; Lah J; Hadži S
    J Mol Biol; 2018 Oct; 430(21):4369-4386. PubMed ID: 30205092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isolation and optimization of camelid single-domain antibodies: Dirk Saerens' work on nanobodies.
    Saerens D
    World J Biol Chem; 2010 Jul; 1(7):235-8. PubMed ID: 21537479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform.
    Pekar L; Busch M; Valldorf B; Hinz SC; Toleikis L; Krah S; Zielonka S
    MAbs; 2020; 12(1):1812210. PubMed ID: 32887531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell selection and characterization of a novel human endothelial cell specific nanobody.
    Ahmadvand D; Rasaee MJ; Rahbarizadeh F; Kontermann RE; Sheikholislami F
    Mol Immunol; 2009 May; 46(8-9):1814-23. PubMed ID: 19249099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.